Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

    ArborGen Holdings

    MCap

    NZD77m

    Last close

    NZD0.15

    ▲ 0.01 (7.14%)

    ICL Group

    MCap

    USD5,729m

    Last close

    USD4.44

    ▲ 0.29 (6.99%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – Adherium

Executive Interview – Adherium

Adherium (ADR.ASX) is an ASX-listed digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Adherium’s market-leading Smartinhaler platform has been independently proven to improve adherence to inhaled medications and improve health outcomes in chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). With an existing 10-year commercial product development and supply agreement with AstraZeneca (AZN) and strong relationships with other global pharmaceutical and medical technology companies and key opinion leaders (KOLs) through sales into the clinical trial sector, Adherium is positioned for strong revenue growth. The company listed on the ASX in August 2015, raising A$35m at A$0.50/share, including a US$3m investment by AZN.

< Previous
Next >

You may also be interested in these:

Consumer

Unlocking London’s hidden tunnels: Investing in a major underground tourist attraction
sharesoc pic

Investment Companies

ShareSoc webinar – The Biotech Growth Trust

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free